[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100374967":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":29,"locations":35,"responsibleParty":62,"collaborators":64,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":20,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":20,"maxAge":20,"enrollmentInfo":78,"targetDuration":20,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"iCell Gene Therapeutics","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"BCMA-CD19 cCAR","EXPERIMENTAL","Dose escalation phase: BCMA-CD19 cCAR T cells transduced with a lentiviral vector to express two distinct units of BCMA and CD19 CARs on a T cell with an escalation approach, 2e6 to 10e6 CAR-T cells\u002Fkg",[13],"Biological: BCMA-CD19 cCAR T cells",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","BCMA-CD19 cCAR T cells","BCMA-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy",[9],null,[22,26],{"name":23,"affiliation":24,"role":25},"Hongyu Zhang, MD\u002FPhD","Peking University Shenzhen Hospital, China","PRINCIPAL_INVESTIGATOR",{"name":27,"affiliation":28,"role":25},"Fang Liu, MD\u002FPhD","Chengdu Military General Hospital",[30],{"name":31,"role":32,"phone":33,"phoneExt":20,"email":34},"Kevin Pinz, MS","CONTACT","6315386218","kevin.pinz@icellgene.com",[36,51],{"facility":24,"status":37,"city":38,"state":39,"zip":20,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Shenzhen","Guangdong","China","CN",{"type":43,"coordinates":44},"Point",[45,46],114.0683,22.54554,{"lat":46,"lon":45},[49],{"name":23,"role":32,"phone":20,"phoneExt":20,"email":50},"Hongyu.Zhang@pkuszh.com",{"facility":28,"status":37,"city":52,"state":53,"zip":20,"country":40,"countryCode":41,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"Chengdu","Sichuan",{"type":43,"coordinates":55},[56,57],104.06667,30.66667,{"lat":57,"lon":56},[60],{"name":27,"role":32,"phone":20,"phoneExt":20,"email":61},"lfyh2006@yahoo.com",{"type":63,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[65,67],{"name":66,"class":6},"iCAR Bio Therapeutics Ltd.",{"name":68,"class":69},"Peking University Shenzhen Hospital","OTHER","100374967","phase-1-bcma-cd19-ccar-in-multiple-myeloma-and-plasmacytoid-lymphoma-100374967",false,"NCT04162353","BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma","BCMA-CD19 cCAR in Relapsed and \u002For Refractory Multiple Myeloma and Plasmacytoid Lymphoma","Inclusion Criteria:\n\n* Signed written informed consent; Patients volunteer to participate in the research\n* Diagnosis is mainly based on the World Health Organization (WHO) 2008\n* Patients have exhausted standard therapeutic options\n* Systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 1 weeks\n* Female must be not pregnant during the study\n\nExclusion Criteria:\n\n* Patients declining to consent for treatment\n* Prior solid organ transplantation\n* Potentially curative therapy including chemotherapy or hematopoietic cell transplant\n* Prior treatment with BCMAxCD3 or CD19xCD3 bispecific agents","ALL",{"count":79,"type":80},12,"ESTIMATED","INTERVENTIONAL",[83],"PHASE1","This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and\u002For refractory multiple myeloma and plasmacytoid lymphoma.",[86,87,88],"Multiple Myeloma in Relapse","Refractory Multiple Myeloma","Plasmacytoid; Lymphoma",[90,91,17,92,93],"BCMA","CD19","multiple myeloma","plasmacytoid lymphoma","2025-09-10",{"date":96,"type":97},"2025-09-16","ACTUAL",{"date":99,"type":97},"2019-07-01",{"date":101,"type":80},"2026-07",{"name":5,"class":6},2]